{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T13:21:41Z","timestamp":1787664101983,"version":"build-2736575974"},"reference-count":155,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Traditional treatments for lung cancer include surgery, radiotherapy, chemotherapy, and targeted therapies (such as Erlotinib, Gefitinib, and Crizotinib), as well as immunotherapy (such as Nivolumab and Pembrolizumab). However, these approaches face challenges such as drug resistance, limited efficacy, and significant side effects, making it difficult to improve long-term prognosis. Therefore, tumor vaccines, as a novel immunotherapy strategy, have become a focus of research, aiming to precisely activate anti-tumor immune responses and address the shortcomings of existing treatments. In recent years, mRNA vaccine technology has developed rapidly, especially following the successful application of COVID-19 vaccines, demonstrating its immense potential for rapid development and large-scale production. mRNA cancer vaccines induce durable anti-tumor immune responses and reshape the tumor microenvironment by delivering mRNA encoding tumor-specific antigens, enabling targeted therapy. Through the dual synergistic pathways of direct local modulation by the vector\/encoded factors and secondary effects mediated by antigen-specific T-cell activation, the tumor microenvironment is reshaped, thereby inducing durable antitumor immune responses. Against this background, this review systematically evaluates the current status and prospects of mRNA vaccines in lung cancer treatment, with a focus on their progress in precisely modulating the tumor microenvironment, identifying novel tumor antigens, discovering immune biomarkers, and related clinical studies. Additionally, the review discusses the process optimization of lipid nanoparticle (LNP) delivery systems, aiming to provide theoretical support and practical guidance for the development of safe and effective therapeutic vaccine platforms for lung cancer.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1916788","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T12:49:03Z","timestamp":1787662143000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapeutic mRNA vaccines for lung cancer: reshaping the tumor microenvironment to enhance anti-tumor immunity"],"prefix":"10.3389","volume":"17","author":[{"given":"Hao","family":"Wu","sequence":"first","affiliation":[{"name":"Key Laboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Shulan International Medical College, Zhejiang Shuren University","place":["Hangzhou, China"]},{"name":"Zhejiang Chinese Medical University","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiqi","family":"Weng","sequence":"additional","affiliation":[{"name":"Key Laboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Shulan International Medical College, Zhejiang Shuren University","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyi","family":"Gu","sequence":"additional","affiliation":[{"name":"Key Laboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Shulan International Medical College, Zhejiang Shuren University","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyuan","family":"Wang","sequence":"additional","affiliation":[{"name":"Key Laboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Shulan International Medical College, Zhejiang Shuren University","place":["Hangzhou, China"]},{"name":"School of Basic Medicine and Forensic Medicine, Hangzhou Medical College","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Ma","sequence":"additional","affiliation":[{"name":"Key Laboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Shulan International Medical College, Zhejiang Shuren University","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxuan","family":"Li","sequence":"additional","affiliation":[{"name":"Key Laboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Shulan International Medical College, Zhejiang Shuren University","place":["Hangzhou, China"]},{"name":"Zhejiang Chinese Medical University","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotian","family":"Tie","sequence":"additional","affiliation":[{"name":"Key Laboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Shulan International Medical College, Zhejiang Shuren University","place":["Hangzhou, China"]},{"name":"Zhejiang Chinese Medical University","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongmin","family":"Huang","sequence":"additional","affiliation":[{"name":"Key Laboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Shulan International Medical College, Zhejiang Shuren University","place":["Hangzhou, China"]},{"name":"Zhejiang Chinese Medical University","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keda","family":"Chen","sequence":"additional","affiliation":[{"name":"Key Laboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Shulan International Medical College, Zhejiang Shuren University","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2022.05.010","article-title":"Molecular subtyping of small cell lung cancer","volume":"86","author":"Liang","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00798-3","article-title":"The global burden of lung cancer: current status and future trends","volume":"20","author":"Leiter","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/nejme2305762","article-title":"Perioperative immunotherapy - a KEY toward improved outcomes for early-stage lung cancer","volume":"389","author":"Lovly","year":"2023","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1891\/9780826145987.0003","article-title":"The current therapeutic cancer vaccines landscape in non-small cell lung cancer","volume":"155","author":"Chen","year":"2024","journal-title":"Int J Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13045-024-01581-2","article-title":"Dual blockade immunotherapy targeting PD-1\/PD-L1 and CTLA-4 in lung cancer","volume":"17","author":"Cheng","year":"2024","journal-title":"J Hematol Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2021.101276","article-title":"p.G12C KRAS mutation prevalence in non-small cell lung cancer: contribution from interregional variability and population substructures among Hispanics","volume":"15","author":"Ruiz-Pati\u00f1o","year":"2022","journal-title":"Transl Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-020-09915-5","article-title":"Molecular epidemiology and diagnostics of KRAS mutations in human cancer","volume":"39","author":"Timar","year":"2020","journal-title":"Cancer Metastasis Rev"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1158\/1538-7445.am2024-1746","article-title":"KRAS mutant lung adenocarcinoma is associated with distinct mutational signature profiles","volume":"84","author":"Woodhouse","year":"2024"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204619","article-title":"Adagrasib in non-small-cell lung cancer harboring a KRAS(G12C) mutation","volume":"387","author":"J\u00e4nne","year":"2022","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01497","article-title":"First-line immunotherapy for non-small-cell lung cancer","volume":"40","author":"Reck","year":"2022","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/s41392-022-01136-2","article-title":"Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response","volume":"7","author":"Wang","year":"2022","journal-title":"Signal Transduction Targeted Ther"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-022-02568-y","article-title":"Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States","volume":"42","author":"Yang","year":"2023","journal-title":"J Exp Clin Cancer Research: CR"},{"key":"B13","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41392-022-00950-y","article-title":"Advances in COVID-19 mRNA vaccine development","volume":"7","author":"Fang","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"B14","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1038\/s41586-026-10599-0","article-title":"Immunological mechanisms of mRNA vaccines for infectious diseases","volume":"654","author":"Locci","year":"2026","journal-title":"Nature"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1384","article-title":"mRNA vaccine in cancer therapy: current advance and future outlook","volume":"13","author":"Li","year":"2023","journal-title":"Clin Transl Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2207841119","article-title":"Lipid nanoparticle-mediated lymph node-targeting delivery of mRNA cancer vaccine elicits robust CD8(+) T cell response","volume":"119","author":"Chen","year":"2022","journal-title":"Proc Natl Acad Sci USA"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1097\/ot9.0000000000000014","article-title":"Development of therapeutic cancer vaccines using nanomicellar preparations","volume":"9","author":"Qin","year":"2023","journal-title":"Oncol Trans Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41563-026-02628-0","article-title":"A metabolic boost to mRNA vaccines","author":"Chada","year":"2026","journal-title":"Nat Mater"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/med.21765","article-title":"Understanding the tumor microenvironment for effective immunotherapy","volume":"41","author":"Sadeghi Rad","year":"2021","journal-title":"Med Res Rev"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1097\/ot9.0000000000000063","article-title":"Remodeling tumor-associated macrophages in the tumor microenvironment","volume":"10","author":"Chen","year":"2024","journal-title":"Oncol Trans Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s13046-025-03377-9","article-title":"Tumor-associated macrophages remodel the suppressive tumor immune microenvironment and targeted therapy for immunotherapy","volume":"44","author":"Yang","year":"2025","journal-title":"J Exp Clin Cancer Res"},{"key":"B22","doi-asserted-by":"publisher","first-page":"LB352","DOI":"10.1158\/1538-7445.am2024-lb352","article-title":"Abstract LB352: Unraveling therapeutic potentials of mRNA-based cancer vaccine concurrently targeting heterogeneous KRAS mutant cancer","volume":"84","author":"Lim","year":"2024"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01330-9","article-title":"Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study","volume":"27","author":"Li","year":"2021","journal-title":"Nat Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.21037\/jtd-22-1113","article-title":"Identification of tumor antigens and immune subtypes in lung squamous cell carcinoma for mRNA vaccine development","volume":"14","author":"Zhao","year":"2022","journal-title":"J Thorac Dis"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.actbio.2023.07.059","article-title":"Immunotherapeutic treatment of lung cancer and bone metastasis with a mPLA\/mRNA tumor vaccine","volume":"169","author":"Ma","year":"2023","journal-title":"Acta Biomater"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e163347","DOI":"10.1172\/jci.insight.163347","article-title":"Consecutive BNT162b2 mRNA vaccination induces short-term epigenetic memory in innate immune cells","volume":"7","author":"Yamaguchi","year":"2022","journal-title":"JCI Insight"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105543","article-title":"Nanostructured lipid carriers based mRNA vaccine leads to a T cell-inflamed tumour microenvironment favourable for improving PD-1\/PD-L1 blocking therapy and long-term immunity in a cold tumour model","volume":"112","author":"Fournier","year":"2025","journal-title":"EBioMedicine"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202300121","article-title":"Rethinking antigen source: cancer vaccines based on whole tumor cell\/tissue lysate or whole tumor cell","volume":"10","author":"Diao","year":"2023","journal-title":"Adv Sci (Weinh)"},{"key":"B29","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41541-023-00792-x","article-title":"Bringing immunofocusing into focus","volume":"9","author":"Musunuri","year":"2024","journal-title":"NPJ Vaccines"},{"key":"B30","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41392-023-01674-3","article-title":"Therapeutic cancer vaccines: advancements, challenges, and prospects","volume":"8","author":"Fan","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-025-01316-4","article-title":"Eliciting antitumor immunity via therapeutic cancer vaccines","volume":"22","author":"Peng","year":"2025","journal-title":"Cell Mol Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2006.01.013","article-title":"Phase I trial of sequential administration of recombinant DNA and adenovirus expressing L523S protein in early stage non-small-cell lung cancer","volume":"13","author":"Nemunaitis","year":"2006","journal-title":"Mol Ther"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.11.001","article-title":"Neoadjuvant gene-mediated cytotoxic immunotherapy for non-small-cell lung cancer: safety and immunologic activity","volume":"29","author":"Predina","year":"2021","journal-title":"Mol Ther"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6600806","article-title":"L523S, an RNA-binding protein as a potential therapeutic target for lung cancer","volume":"88","author":"Wang","year":"2003","journal-title":"Br J Cancer"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2010-0026rt","article-title":"Gene therapy for mesothelioma and lung cancer","volume":"42","author":"Vachani","year":"2010","journal-title":"Am J Respir Cell Mol Biol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.815596","article-title":"Identification of tumor antigens and immune subtypes in lung adenocarcinoma for mRNA vaccine development","volume":"10","author":"Xu","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad193","article-title":"Identification of immune subtypes and candidate mRNA vaccine antigens in small cell lung cancer","volume":"28","author":"Wei","year":"2023","journal-title":"Oncologist"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.755401","article-title":"Potential immune biomarker candidates and immune subtypes of lung adenocarcinoma for developing mRNA vaccines","volume":"12","author":"Wang","year":"2021","journal-title":"Front Immunol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/cac2.12250","article-title":"Ferroptosis in cancer and cancer immunotherapy","volume":"42","author":"Zhao","year":"2022","journal-title":"Cancer Commun (Lond)"},{"key":"B40","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/s41392-022-01046-3","article-title":"Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy","volume":"7","author":"Gao","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"B41","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1038\/s41598-024-53622-y","article-title":"Discovery of lung adenocarcinoma tumor antigens and ferroptosis subtypes for developing mRNA vaccines","volume":"14","author":"Chen","year":"2024","journal-title":"Sci Rep"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2019.09.015","article-title":"Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer","volume":"61","author":"Harrison","year":"2020","journal-title":"Semin Cancer Biol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100395","article-title":"Consensus for HER2 alterations testing in non-small-cell lung cancer","volume":"7","author":"Ren","year":"2022","journal-title":"ESMO Open"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1042072","article-title":"Characteristics of the immunogenicity and tumor immune microenvironment in HER2-amplified lung adenocarcinoma","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1080\/15384047.2019.1702403","article-title":"Harnessing the vulnerabilities of p53 mutants in lung cancer - focusing on the proteasome: a new trick for an old foe","volume":"21","author":"Oduah","year":"2020","journal-title":"Cancer Biol Ther"},{"key":"B46","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1186\/s13046-020-01741-5","article-title":"Evodiamine suppresses non-small cell lung cancer by elevating CD8(+) T cells and downregulating the MUC1-C\/PD-L1 axis","volume":"39","author":"Jiang","year":"2020","journal-title":"J Exp Clin Cancer Res"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-2024-1242","article-title":"Cytokine-driven modulation of WT1 and IL-10 in lung cancer progression","volume":"14","author":"Izaguirre-Alvarez","year":"2025","journal-title":"Transl Lung Cancer Res"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.7150\/thno.84710","article-title":"Global analysis of HLA-A2 restricted MAGE-A3 tumor antigen epitopes and corresponding TCRs in non-small cell lung cancer","volume":"13","author":"Zhang","year":"2023","journal-title":"Theranostics"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.ads4227","article-title":"MAGE-A4 induces non-small cell lung cancer and tumor-promoting plasma cell accumulation","volume":"11","author":"Armstrong","year":"2025","journal-title":"Sci Adv"},{"key":"B50","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/s41577-024-01091-9","article-title":"Vax-Innate: improving therapeutic cancer vaccines by modulating T cells and the tumour microenvironment","volume":"25","author":"Baharom","year":"2025","journal-title":"Nat Rev Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.3c05635","article-title":"mRNA cancer vaccines: Construction and boosting strategies","volume":"17","author":"Liu","year":"2023","journal-title":"ACS Nano"},{"key":"B52","doi-asserted-by":"publisher","first-page":"e2005191118","DOI":"10.1073\/pnas.2005191118","article-title":"Delivery of mRNA vaccine with a lipid-like material potentiates antitumor efficacy through Toll-like receptor 4 signaling","volume":"118","author":"Zhang","year":"2021","journal-title":"PNAS"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1080\/10717544.2023.2219869","article-title":"Negatively charged phospholipids doped liposome delivery system for mRNA with high transfection efficiency and low cytotoxicity","volume":"30","author":"Wang","year":"2023","journal-title":"Drug Delivery"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.3390\/vaccines9091007","article-title":"Development of an mRNA-LNP vaccine against SARS-CoV-2: Evaluation of immune response in mouse and rhesus macaque","volume":"9","author":"Naderi Sohi","year":"2021","journal-title":"Vaccines"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.cell.2020.07.024","article-title":"A thermostable mRNA vaccine against COVID-19","volume":"182","author":"Zhang","year":"2020","journal-title":"Cell"},{"key":"B56","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/s41392-023-01432-5","article-title":"Monkeypox virus quadrivalent mRNA vaccine induces immune response and protects against vaccinia virus","volume":"8","author":"Sang","year":"2023","journal-title":"Signal Transduction Targeted Ther"},{"key":"B57","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41541-023-00733-8","article-title":"mRNA-LNP vaccination-based immunotherapy augments CD8(+) T cell responses against HPV-positive oropharyngeal cancer","volume":"8","author":"Qiu","year":"2023","journal-title":"NPJ Vaccines"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.3390\/vaccines11091465","article-title":"Sending a message: Use of mRNA vaccines to target the tumor immune microenvironment","volume":"11","author":"Ramirez","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.actbio.2025.01.040","article-title":"Lung-targeted delivery of PTEN mRNA combined with anti-PD-1-mediated immunotherapy for in situ lung cancer treatment","volume":"194","author":"Hu","year":"2025","journal-title":"Acta Biomater"},{"key":"B60","doi-asserted-by":"publisher","first-page":"3782","DOI":"10.3390\/cancers13153782","article-title":"Epigenetic reprogramming of tumor-associated fibroblasts in lung cancer: Therapeutic opportunities","volume":"13","author":"Alcaraz","year":"2021","journal-title":"Cancers"},{"key":"B61","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41568-018-0081-9","article-title":"The lung microenvironment: An important regulator of tumour growth and metastasis","volume":"19","author":"Altorki","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5698","article-title":"Role of tumor microenvironment in cancer progression and therapeutic strategy","volume":"12","author":"Wang","year":"2023","journal-title":"Cancer Med"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-24-379","article-title":"Tumor immune microenvironment analysis of non-small cell lung cancer development through multiplex immunofluorescence","volume":"13","author":"Zhao","year":"2024","journal-title":"Trans Lung Cancer Res"},{"key":"B64","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1186\/s13046-025-03519-z","article-title":"Immunotherapy resistance in non-small cell lung cancer: From mechanisms to therapeutic opportunities","volume":"44","author":"Wang","year":"2025","journal-title":"J Exp Clin Cancer Res"},{"key":"B65","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/s41392-025-02280-1","article-title":"Immune evasion in cancer: Mechanisms and cutting-edge therapeutic approaches","volume":"10","author":"Tufail","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1002\/fsn3.954","article-title":"Effect of silkworm peptide on inducting M1 type polarization and Th1 activation via TLR2-induced MyD88-dependent pathway","volume":"7","author":"Zhu","year":"2019","journal-title":"Food Sci Nutr"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202307225","article-title":"Photosynthetic bacteria-hitchhiking 2D iMXene-mRNA vaccine to enable photo-immunogene cancer therapy","volume":"11","author":"Zhang","year":"2024","journal-title":"Advanced Sci (Weinheim Baden-Wurttemberg Germany)"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109367","article-title":"The main battlefield of mRNA vaccine - Tumor immune microenvironment","volume":"113","author":"Li","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1158\/1538-7445.am2018-1758","article-title":"Intratumoral IL-12 mRNA promotes cytotoxic T cell-dependent anti-tumor immunity and enhances responses to PD-L1 blockade in pre-clinical models","volume":"78","author":"Hewitt","year":"2018"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-022-03144-1","article-title":"Interleukin-12 as an in situ cancer vaccine component: A review","volume":"71","author":"Cheng","year":"2022","journal-title":"Cancer Immunology Immunotherapy CII"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/s41565-023-01580-3","article-title":"Inhalable extracellular vesicle delivery of IL-12 mRNA to treat lung cancer and promote systemic immunity","volume":"19","author":"Liu","year":"2024","journal-title":"Nat Nanotechnol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217111","article-title":"Intratumoral injection of mRNA encoding survivin in combination with STAT3 inhibitor stattic enhances antitumor effects","volume":"598","author":"Li","year":"2024","journal-title":"Cancer Lett"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.8654","article-title":"FGL2 is positively correlated with enhanced antitumor responses mediated by T cells in lung adenocarcinoma","volume":"8","author":"Yuan","year":"2020","journal-title":"PeerJ"},{"key":"B74","doi-asserted-by":"publisher","first-page":"6560","DOI":"10.3390\/ijms22126560","article-title":"The impact of the tumor microenvironment on macrophage polarization in cancer metastatic progression","volume":"22","author":"Wang","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.3390\/cells9051303","article-title":"Lung tumor cell-derived exosomes promote M2 macrophage polarization","volume":"9","author":"Pritchard","year":"2020","journal-title":"Cells"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2022.06.011","article-title":"Tumor cells modulate macrophage phenotype in a novel in vitro co-culture model of the NSCLC tumor microenvironment","volume":"17","author":"Park","year":"2022","journal-title":"J Thorac Oncol Off Publ Int Assoc For Study Lung Cancer"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.jncc.2022.10.002","article-title":"Characteristics of tumor microenvironment and novel immunotherapeutic strategies for non-small cell lung cancer","volume":"2","author":"Wang","year":"2022","journal-title":"J Natl Cancer Center"},{"key":"B78","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.3390\/cancers13081850","article-title":"Recruitment and expansion of Tregs cells in the tumor environment-how to target them","volume":"13","author":"Cinier","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-06033-6","article-title":"mRNA vaccines in the context of cancer treatment: From concept to application","volume":"23","author":"Fu","year":"2025","journal-title":"J Transl Med"},{"key":"B80","doi-asserted-by":"publisher","first-page":"eaba9772","DOI":"10.1126\/scitranslmed.aba9772","article-title":"Reactivation of the tumor suppressor PTEN by mRNA nanoparticles enhances antitumor immunity in preclinical models","volume":"13","author":"Lin","year":"2021","journal-title":"Sci Transl Med"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.5c09365","article-title":"mRNA-based vaccination drives in vivo dendritic cell reprogramming and selective cytotoxic T lymphocyte modulation for enhanced antitumor immunity","volume":"19","author":"Zhang","year":"2025","journal-title":"ACS Nano"},{"key":"B82","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41417-021-00303-x","article-title":"Key chemokines direct migration of immune cells in solid tumors","volume":"29","author":"Kohli","year":"2022","journal-title":"Cancer Gene Ther"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.5c14753","article-title":"Reprogramming immunosuppressive niches and the cancer immunity cycle in pancreatic cancer with neoantigen mRNA plus immune adjuvant nanocarrier strategies","volume":"19","author":"Nel","year":"2025","journal-title":"ACS Nano"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1093\/jimmun\/vkag141.1397","article-title":"Targeted immunotherapy for regulatory T cells 2307761","volume":"215","author":"Maule","year":"2026","journal-title":"J Immunol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2020.03.021","article-title":"Analysis of lung adenocarcinoma subtypes based on immune signatures identifies clinical implications for cancer therapy","volume":"17","author":"Xu","year":"2020","journal-title":"Mol Ther Oncolytics"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.18632\/aging.102814","article-title":"Analysis of immune-related signatures of lung adenocarcinoma identified two distinct subtypes: Implications for immune checkpoint blockade therapy","volume":"12","author":"Wang","year":"2020","journal-title":"Aging"},{"key":"B87","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1038\/s41467-021-22801-0","article-title":"Single-cell profiling of tumor heterogeneity and the microenvironment in advanced non-small cell lung cancer","volume":"12","author":"Wu","year":"2021","journal-title":"Nat Commun"},{"key":"B88","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1186\/s12885-023-11580-0","article-title":"Characterization of genomic instability-related genes predicts survival and therapeutic response in lung adenocarcinoma","volume":"23","author":"Li","year":"2023","journal-title":"BMC Cancer"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.4093182","article-title":"Recognition of immune-related tumor antigens and immune subtypes for mRNA vaccine development in lung adenocarcinoma","volume":"20","author":"Zhao","year":"2022","journal-title":"Comput Struct Biotechnol J"},{"key":"B90","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s13046-021-01987-7","article-title":"Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer","volume":"40","author":"Zhang","year":"2021","journal-title":"J Exp Clin Cancer Res CR"},{"key":"B91","doi-asserted-by":"publisher","first-page":"e002973","DOI":"10.1136\/jitc-2021-002973","article-title":"Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1\/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760)","volume":"9","author":"Leighl","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B92","doi-asserted-by":"publisher","first-page":"e004025","DOI":"10.1136\/jitc-2021-004025","article-title":"Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study)","volume":"10","author":"Seto","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: From T cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B94","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s40779-022-00416-w","article-title":"Personalized pancreatic cancer therapy: From the perspective of mRNA vaccine","volume":"9","author":"Huang","year":"2022","journal-title":"Mil Med Res"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1038\/d41591-023-00072-0","article-title":"Personalized anti-cancer vaccine combining mRNA and immunotherapy tested in melanoma trial","volume":"29","author":"Carvalho","year":"2023","journal-title":"Nat Med"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202303261","article-title":"Lipid nanoparticle (LNP) enables mRNA delivery for cancer therapy","volume":"35","author":"Zong","year":"2023","journal-title":"Adv Mater"},{"key":"B97","doi-asserted-by":"publisher","first-page":"9471","DOI":"10.1038\/s41467-024-53914-x","article-title":"Charge-assisted stabilization of lipid nanoparticles enables inhaled mRNA delivery for mucosal vaccination","volume":"15","author":"Liu","year":"2024","journal-title":"Nat Commun"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-024-00990-9","article-title":"Combination therapy of KRAS G12V mRNA vaccine and pembrolizumab: Clinical benefit in patients with advanced solid tumors","volume":"34","author":"Wang","year":"2024","journal-title":"Cell Res"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102309","article-title":"KRAS inhibitors- yes but what next? Direct targeting of KRAS- vaccines, adoptive T cell therapy and beyond","volume":"101","author":"Nagasaka","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"B100","doi-asserted-by":"publisher","first-page":"e002035","DOI":"10.1136\/jitc-2020-002035","article-title":"Development of a CD8 co-receptor independent T-cell receptor specific for tumor-associated antigen MAGE-A4 for next generation T-cell-based immunotherapy","volume":"9","author":"Davari","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.2147\/cmar.s302928","article-title":"High tumor burden\" in metastatic non-small cell lung cancer: Defining the concept","volume":"13","author":"Higuera G\u00f3mez","year":"2021","journal-title":"Cancer Manag Res"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1507501","article-title":"Targeting T cell exhaustion: Emerging strategies in non-small cell lung cancer","volume":"15","author":"Liu","year":"2024","journal-title":"Front Immunol"},{"key":"B103","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3390\/vaccines11020280","article-title":"Improved DNA vaccine delivery with needle-free injection systems","volume":"11","author":"Ledesma-Feliciano","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"B104","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s40425-019-0520-5","article-title":"Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer","volume":"7","author":"Papachristofilou","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B105","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s00262-019-02315-x","article-title":"A phase I\/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB\/IV non-small cell lung cancer","volume":"68","author":"Sebastian","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"B106","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2025-CT013","article-title":"Phase I trial evaluating BNT116, a TAA-encoding mRNA vaccine, in combination with cemiplimab in frail patients with advanced non-small cell lung cancer (NSCLC) Free","volume-title":"Cancer Research","author":"Dziadziuszko","year":"2025"},{"key":"B107","unstructured":"Inhaled Mrna Tumor-Associated Antigen Dry Powder Vaccine in Advanced Lung Cancer and Lung Metastasis of Solid Tumors. Clinicaltrials.Gov Identifier: NCT06928922\n          \n          \n          \n          2025"},{"key":"B108","unstructured":"Dose escalation study evaluating the safety, tolerability, and preliminary efficacy of ABOR2013 monotherapy or in combination with PD-1 monoclonal antibody in advanced non-small cell lung cancer with EGFR positive mutation. ChiCTR2300071001\n          \n          \n          \n          2023"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.am2025-852","article-title":"A novel EGFR neoantigen-specific mRNA cancer vaccine demonstrates immunogenicity and anti-tumor efficacy in human","volume":"85","author":"Liang","year":"2025","journal-title":"Cancer Res"},{"key":"B110","unstructured":"Safety and Tolerability of CVHNLC Plus Pembrolizumab in Patients With Squamous non Small-Cell Lung Cancer (Sqnsclc). Clinicaltrials.Gov Identifier: NCT07073183\n          \n          \n          \n          2025"},{"key":"B111","unstructured":"A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With non-Small Cell Lung Cancer (V940-002) (Interpath-002). Clinicaltrials.Gov Identifier: NCT06077760\n          \n          \n          \n          2023"},{"key":"B112","unstructured":"A Study of Mrna-5671\/\u200bV941 as Monotherapy and in Combination With Pembrolizumab (V941-001). Clinicaltrials.Gov Identifier: NCT03948763\n          \n          \n          \n          2025"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202202688","article-title":"Polymer-based mRNA delivery strategies for advanced therapies","volume":"12","author":"Yang","year":"2023","journal-title":"Adv Healthc Mater"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2024.124344","article-title":"Design of novel chiral self-assembling peptides to explore the efficiency and mechanism of mRNA-FIPV vaccine delivery vehicles","volume":"660","author":"Lu","year":"2024","journal-title":"Int J Pharm"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.887125","article-title":"mRNA vaccines: The dawn of a new era of cancer immunotherapy","volume":"13","author":"Deng","year":"2022","journal-title":"Front Immunol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.114027","article-title":"Efficacy versus immunogenicity of LNP-mediated delivery of mRNA and self-amplifying RNA upon intravitreal injection in the mouse eye","volume":"385","author":"Li","year":"2025","journal-title":"J Control Release"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2200674","article-title":"Safety and efficacy of a third dose of BNT162b2 Covid-19 vaccine","volume":"386","author":"Moreira","year":"2022","journal-title":"N Engl J Med"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2109522","article-title":"Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents","volume":"385","author":"Ali","year":"2021","journal-title":"N Engl J Med"},{"key":"B119","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1186\/s12951-025-03201-8","article-title":"The immunogenic potential of an optimized mRNA lipid nanoparticle formulation carrying sequences from virus and protozoan antigens","volume":"23","author":"Fernandes","year":"2025","journal-title":"J Nanobiotechnology"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1029069","article-title":"mRNA vaccines for cancer immunotherapy","volume":"13","author":"Vishweshwaraiah","year":"2022","journal-title":"Front Immunol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1039\/d4tb02101k","article-title":"Zeolitic imidazolate frameworks enhanced transfection efficiency of mRNA loaded lipid nanoparticles","volume":"13","author":"Singh","year":"2025","journal-title":"J Mater Chem B"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2022.03.021","article-title":"Intratumoral delivery of IL-12 and IL-27 mRNA using lipid nanoparticles for cancer immunotherapy","volume":"345","author":"Liu","year":"2022","journal-title":"J Control Release"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1002\/wnan.1992","article-title":"Insights into the formulation of lipid nanoparticles for the optimization of mRNA therapeutics","volume":"16","author":"Jiao","year":"2024","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2024.01.020","article-title":"Lymph node macrophages drive innate immune responses to enhance the anti-tumor efficacy of mRNA vaccines","volume":"32","author":"Kubara","year":"2024","journal-title":"Mol Ther"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.113892","article-title":"Tertiary amine N-oxide zwitterionic lipids facilitate muscle-selective mRNA vaccine delivery for enhancing cDC1-mediated antitumor efficacy","volume":"384","author":"Yang","year":"2025","journal-title":"J Control Release"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2022.07.007","article-title":"mRNA-LNP vaccines tuned for systemic immunization induce strong antitumor immunity by engaging splenic immune cells","volume":"30","author":"Bevers","year":"2022","journal-title":"Mol Ther"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-023-01131-0","article-title":"Screening for lipid nanoparticles that modulate the immune activity of helper T cells towards enhanced antitumour activity","volume":"8","author":"Zhu","year":"2024","journal-title":"Nat BioMed Eng"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.114365","article-title":"Cell-specific mRNA delivery via nanobody-functionalized lipid nanoparticles","volume":"388","author":"Chen","year":"2025","journal-title":"J Control Release"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1002\/smtd.202401712","article-title":"Cholesterol-derived mannosylated polypeptide-formed lipid nanoparticles for efficient in vivo mRNA delivery","volume":"9","author":"Zeng","year":"2025","journal-title":"Small Methods"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202309917","article-title":"Design of PD-L1-targeted lipid nanoparticles to turn on PTEN for efficient cancer therapy","volume":"11","author":"Kim","year":"2024","journal-title":"Adv Sci (Weinh)"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2025.03.018","article-title":"CD47 peptide-cloaked lipid nanoparticles promote cell-specific mRNA delivery","volume":"33","author":"Papp","year":"2025","journal-title":"Mol Ther"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2020.07.001","article-title":"Development of lipid-like materials for RNA delivery based on intracellular environment-responsive membrane destabilization and spontaneous collapse","author":"Tanaka","year":"2020","journal-title":"Adv Drug Delivery Rev"},{"key":"B133","doi-asserted-by":"publisher","first-page":"105547","DOI":"10.1016\/j.jddst.2024.105547","article-title":"The optimization strategies of LNP-mRNA formulations: Development and challenges for further application","volume":"95","author":"Wang","year":"2024","journal-title":"J Drug Delivery Sci Technol"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1039\/d3cs00194f","article-title":"Nucleic acid degradation as barrier to gene delivery: A guide to understand and overcome nuclease activity","volume":"53","author":"Zhang","year":"2024","journal-title":"Chem Soc Rev"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-micro-041020-113308","article-title":"Compartmentalization of RNA degradosomes in bacteria controls accessibility to substrates and ensures concerted degradation of mRNA to nucleotides","volume":"76","author":"Carpousis","year":"2022","journal-title":"Annu Rev Microbiol"},{"key":"B136","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3390\/nano10020190","article-title":"Immunological and toxicological considerations for the design of liposomes","volume":"10","author":"Inglut","year":"2020","journal-title":"Nanomaterials (Basel Switzerland)"},{"key":"B137","doi-asserted-by":"publisher","first-page":"6615","DOI":"10.3390\/ijms24076615","article-title":"Liposomes in cancer therapy: How did we start and where are we now","volume":"24","author":"Fulton","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2021.101266","article-title":"Exosome-mediated mRNA delivery in vivo is safe and can be used to induce SARS-CoV-2 immunity","volume":"297","author":"Tsai","year":"2021","journal-title":"J Biol Chem"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2020.08.023","article-title":"DP7-C-modified liposomes enhance immune responses and the antitumor effect of a neoantigen-based mRNA vaccine","volume":"328","author":"Zhang","year":"2020","journal-title":"J Controlled Release: Off J Controlled Release Soc"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.4c01171","article-title":"High-throughput in vivo screening identifies differential influences on mRNA lipid nanoparticle immune cell delivery by administration route","volume":"18","author":"Hamilton","year":"2024"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2021.12.008","article-title":"The role of nanoparticle format and route of administration on self-amplifying mRNA vaccine potency","volume":"342","author":"Anderluzzi","year":"2022","journal-title":"J Controlled Release: Off J Controlled Release Soc"},{"key":"B142","doi-asserted-by":"publisher","first-page":"597","DOI":"10.3390\/ijms21020597","article-title":"Immunosurveillance and immunoediting of lung cancer: Current perspectives and challenges","volume":"21","author":"Kunimasa","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-023-00548-5","article-title":"The immunopeptidome landscape associated with T cell infiltration, inflammation and immune editing in lung cancer","volume":"4","author":"Kraemer","year":"2023","journal-title":"Nat Cancer"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-024-01111-8","article-title":"Cancer immune evasion, immunoediting and intratumour heterogeneity","volume":"25","author":"Roerden","year":"2025","journal-title":"Nat Rev Immunol"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(22)00842-x","article-title":"COVID-19 mRNA vaccination and myocarditis or pericarditis","volume":"399","author":"Husby","year":"2022","journal-title":"Lancet (London England)"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2022.09.005","article-title":"Unraveling tumor microenvironment of small-cell lung cancer: Implications for immunotherapy","volume":"86","author":"Li","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"B147","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1186\/s12967-021-03014-x","article-title":"Identification of tumor antigens and immune subtypes in lower grade gliomas for mRNA vaccine development","volume":"19","author":"Ye","year":"2021","journal-title":"J Transl Med"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"key":"B149","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s12943-021-01452-1","article-title":"Tumor-antigens and immune landscapes identification for prostate adenocarcinoma mRNA vaccine","volume":"20","author":"Zheng","year":"2021","journal-title":"Mol Cancer"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104772","article-title":"The promise of mRNA vaccines in cancer treatment: Technology, innovations, applications, and future directions","volume":"212","author":"Tang","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1021\/acs.nanolett.9b04246","article-title":"Ionizable lipid nanoparticle-mediated mRNA delivery for human CAR T cell engineering","volume":"20","author":"Billingsley","year":"2020","journal-title":"Nano Lett"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.5b06939","article-title":"Blood exosomes endowed with magnetic and targeting properties for cancer therapy","volume":"10","author":"Qi","year":"2016","journal-title":"ACS Nano"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202007603","article-title":"mRNA delivery of a bispecific single-domain antibody to polarize tumor-associated macrophages and synergize immunotherapy against liver Malignancies","volume":"33","author":"Wang","year":"2021","journal-title":"Adv Mater"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e27194","article-title":"Discovering ferroptosis-associated tumor antigens and ferroptosis subtypes in pancreatic adenocarcinoma to facilitate mRNA vaccine development","volume":"10","author":"Yan","year":"2024","journal-title":"Heliyon"},{"key":"B155","doi-asserted-by":"publisher","first-page":"6158","DOI":"10.1038\/s41467-026-72737-6","article-title":"Ferroptosis-armed dendritic cell vaccines for glioma immunotherapy","volume":"17","author":"Saviuk","year":"2026","journal-title":"Nat Commun"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1916788\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T12:49:05Z","timestamp":1787662145000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1916788\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,25]]},"references-count":155,"alternative-id":["10.3389\/fimmu.2026.1916788"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1916788","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,25]]},"article-number":"1916788"}}